Обоснованность комбинированного применения генно-инженерных биологических препаратов у пациентов с COVID-19


DOI: https://dx.doi.org/10.18565/pharmateca.2021.8.15-19

И.С. Бурашникова

Казанская государственная медицинская академия – филиал ФГБОУ ДПО РМАНПО Минздрава РФ, Казань, Россия, https://orcid.org/0000-0002-8511-5696
В настоящее время отсутствуют данные клинических исследований, позволяющие рекомендовать применение комбинаций генно-инженерных биологических препаратов (ГИБП) при лечении пациентов с COVID-19. Клинические данные о последовательном применении различных ГИБП противоречивы. Комбинированное применение ГИБП может повышать риск угнетения иммунной системы. Применение ингибиторов янус-киназ в комбинации с биологическими базисными противоревматическими препаратами не рекомендуется.

Литература


1. Mehta P., McAuley D.F., Brown M., et al. Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–34. Doi: 10.1016/S0140-6736(20)30628-0.


2. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. Doi: 10.1016/S0140-6736(20)30183-5.


3. Choudhary S., Sharma K., Silakari O. The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. Microb Pathog. 2021;150:104673. Doi: 10.1016/j.micpath.2020.104673.


4. Wolf J., Rose-John S., Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70:11–20. Doi: 10.1016/j.cyto.2014.05.024.


5. Karki R., Sharma B.R., Tuladhar S., et al. Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell. 2021;184(1):149–68.e17. Doi: 10.1016/j.cell.2020.11.025.


6. Wu D., Yang X.O. Th17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. J Microbiol Immunol Infect. 202053(3):368–70. Doi: 10.1016/j.jmii.2020.03.005.


7. Pacha O., Sallman M.A., Evans S.E. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020;20(6):345–46. Doi: 10.1038/s41577-020-0328-z.


8. Liu Y., Yang Y., Zhang C., et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–74. Doi: 10.1007/s11427-020-1643-8.


9. Kritas S.K., Ronconi G., Caraffa A., et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020;34(1):9–14. Doi: 10.23812/20-Editorial-Kritas.


10. Conti P., Caraffa A., Gallenga C.E., et al. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). J Biol Regul Homeost Agents. 2020;34(5):1623–27. Doi: 10.23812/20-34-4EDIT-65.


11. Man S.M., Karki R., Kanneganti T.D. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev. 2017;277:61–75. Doi: 10.1111/imr.12534.


12. Anakinra (Kineret) Prescribing Information. Food and Drug Administration. 2012. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf. (Accessed April 8, 2020).


13. Richardson P., Griffin I., Tucker C., et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–1. Doi: 10.1016/S0140-6736(20)30304-4.


14. Bronte V., Ugel S., Tinazzi E. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130:6409–406. Doi: 10.1172/JCI141772.


15. Maslennikov R., Ivashkin V., Vasilieva E., et al. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19


16. Khani E., Khiali S., Entezari-Maleki T. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. J Clin Pharmacol. 2021;61(4):429–60. Doi: 10.1002/jcph.1822.


17. Siemieniuk R.A., Bartoszko J.J., Ge L., et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980. Doi: 10.1136/bmj.m2980.


18. Kim J.S., Lee J.Y., Yang J.W., et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316–29. Doi: 10.7150/thno.49713.


19. Seif F., Pornour M., Mansouri D. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19. Int Arch Allergy Immunol. 2020;181(8):648–49. Doi: 10.1159/000509198.


20. Gremese E., Alivernini S., Tolusso B., et al. JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. J Leukoc. Biol. 2019;106(5):1063–68. Doi: 10.1002/JLB.5RU0519-145R.


21. Методические рекомендации «Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19) у детей». Версия 2.


22. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 11 (07.05.2021).


23. URL: https://www.covid19treatmentguidelines.nih.gov/immunomodulators/Accessed 06.06.2021


24. URL: https://app.magicapp.org/#/guideline/L4Q5An/rec/Lq4Y0j Accessed 06.06.2021


25. URL: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/clinical-management-covid-19.html#a83


26. Rebonato M.A., D’Adamo F., Capalbo M., Frausini G. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis. Respir. Med. Case Rep. 2020;31:101115. Doi: 10.1016/j.rmcr.2020.101115.


27. Aomar-Millán, Francisco I., et al. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. Intern Emerg Med. 2021;1–10. Doi: 10.1007/s11739-020-02600-z.


28. Maes B., Bosteels C., De Leeuw E., et al. Bart Lambrecht Trials. 2020;21:468. (Published on-line 2020 Jun 3). Doi: 10.1186/s13063-020-04453-5. URL: https://clinicaltrials.gov/ct2/show/study/NCT04330638.


29. URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001963-10/FR


30. URL: https://clinicaltrials.gov/ct2/show/NCT04335305?term=NCT04335305&draw=2&rank=1


31. Rubsamen R., Burkholz S., Massey C., et al. Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome. Front Pharmacol. 2020;11:574703. Doi: 10.3389/fphar.2020.574703.


32. Клинический протокол лечения больных новой коронавирусной инфекцией COVID-19, находящихся на стационарном лечении в медицинских организациях государственной системы здравоохранения города Москвы. 2020.


33. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=aeba7a96-640f-4474-8a57-e343a7d864d3&t


34. URL: https://www.roche.ru/content/dam/rochexx/roche-ru/roche_russia/ru_RU/Instructions/actemra-iv-2021-02-09.pdf


35. Stallmach A., Kortgen A., Gonnert F., et al. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure – a cautionary case series. Crit Care. 2020;24(1):444. Doi: 10.1186/s13054-020-03158-0


36. URL: https://clinicaltrials.gov/ct2/show/NCT04425538?term=infliximab&cond=Covid19&draw=2&rank=1


37. Kennedy N.A., et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021;70(5):865–875. (Published Online First: 22 March 2021). Doi: 10.1136/gutjnl-2021-324388.


38. URL: https://clinicaltrials.gov/ct2/show/NCT04734678?term=infliximab&cond=Covid19&draw=2&rank=2


39. Cingolani A., Tummolo A.M., Montemurro G., et al. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Infection. 2020;48(5):767–71. Doi: 10.1007/s15010-020-01476-7.


40. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8f3091a1-76a1-4bbd-a3db-b96e103ac7b7&t=


41. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fc646e04-eab0-48a2-8a89-978afa294491&t=


Похожие статьи


Бионика Медиа